{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T03:03:19Z","timestamp":1773802999103,"version":"3.50.1"},"reference-count":50,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In the current treatment paradigm, the use of anti-CD38 monoclonal antibodies (mAbs) in frontline has notably increased, for both transplant-ineligible and transplant-eligible patients with newly diagnosed multiple myeloma (NDMM) patients. As a result, patients with multiple myeloma (MM) are frequently exposed to or develop resistance to anti-CD38 mAb therapy during the initial stages of treatment. Here, we review second-line (first relapse) and some third-line (second relapse) therapies for patients with MM with disease progression after exposure to anti-CD38 mAb-based therapy. We discuss therapies including B-cell maturation antigen (BCMA)\u2013targeted and non-BCMA-targeted therapeutic options in the setting of prior anti-CD38 mAb exposure\/refractoriness.<\/jats:p>","DOI":"10.1182\/hematology.2023000444","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:11:37Z","timestamp":1702048297000},"page":"443-449","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Considerations for next therapy after anti-CD38 monoclonal antibodies used as first line"],"prefix":"10.1182","volume":"2023","author":[{"given":"Monique","family":"Hartley-Brown","sequence":"first","affiliation":[{"name":"1 Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ateh","family":"Zinkeng","sequence":"additional","affiliation":[{"name":"1 Dana-Farber Cancer Institute, Boston, MA"},{"name":"2 University of Arizona College of Medicine, Tucson, AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"issue":"4","key":"2023120815070749300_hem2023000444C1","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.2020010439","article-title":"Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE","volume":"139","author":"San-Miguel","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2023120815070749300_hem2023000444C2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","article-title":"Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)","volume":"10","author":"Durie","year":"2020","journal-title":"Blood Cancer J"},{"issue":"10068","key":"2023120815070749300_hem2023000444C3","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"suppl 1","key":"2023120815070749300_hem2023000444C4","doi-asserted-by":"crossref","first-page":"7278","DOI":"10.1182\/blood-2022-162339","article-title":"et al. Daratumumab plus lenalidomide, bortezomib, and dexamethasone (D-RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients (Pts): final analysis of griffin among clinically relevant subgroups","volume":"140","author":"Chari","year":"2022","journal-title":"Blood"},{"issue":"15 suppl","key":"2023120815070749300_hem2023000444C5","doi-asserted-by":"crossref","first-page":"TPS8055","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS8055","article-title":"Bortezomib, lenalidomide, and dexamethasone (VRd)\u00b1daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): a multicenter, randomized, phase III study (PERSEUS)","volume":"37","author":"Sonneveld","year":"2019","journal-title":"J Clin Oncol"},{"issue":"10","key":"2023120815070749300_hem2023000444C6","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","article-title":"Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10218","key":"2023120815070749300_hem2023000444C7","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"2023120815070749300_hem2023000444C8","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","article-title":"Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active- controlled, phase 3 trial","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"2023120815070749300_hem2023000444C9","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.1182\/blood-2022-163483","article-title":"Subcutaneous daratumumab plus pomalidomide and dexamethasone (D-Pd) versus pomalidomide and dexamethasone (Pd) alone in patients with relapsed or refractory multiple myeloma (RRMM): overall survival results from the phase 3 Apollo study [abstract]","volume":"140","author":"Dimopoulos","year":"2022","journal-title":"Blood"},{"issue":"14","key":"2023120815070749300_hem2023000444C10","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/bloodadvances.2023010026","article-title":"Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study","volume":"7","author":"Usmani","year":"2023","journal-title":"Blood Adv"},{"issue":"10","key":"2023120815070749300_hem2023000444C11","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10","key":"2023120815070749300_hem2023000444C12","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1007\/s00277-022-04917-5","article-title":"Anti-CD38 antibody therapy for patients with relapsed\/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes","volume":"101","author":"Leleu","year":"2022","journal-title":"Ann Hematol"},{"issue":"21","key":"2023120815070749300_hem2023000444C13","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood.V124.21.3474.3474","article-title":"Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79","volume":"124","author":"Lammerts van Bueren","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2023120815070749300_hem2023000444C14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41408-021-00478-4","article-title":"A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab","volume":"11","author":"Mikhael","year":"2021","journal-title":"Blood Cancer J"},{"issue":"10292","key":"2023120815070749300_hem2023000444C15","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"2023120815070749300_hem2023000444C16","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41408-023-00797-8","article-title":"Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized phase 3 study","volume":"13","author":"Martin","year":"2023","journal-title":"Blood Cancer J"},{"issue":"11","key":"2023120815070749300_hem2023000444C17","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s40273-021-01068-9","article-title":"Cost effectiveness of triplet selinexor-bortezomib-dexamethasone (XVd) in previously treated multiple myeloma (MM) based on results from the phase III BOSTON trial","volume":"39","author":"Dolph","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"10262","key":"2023120815070749300_hem2023000444C18","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"2023120815070749300_hem2023000444C19","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/14656566.2019.1707184","article-title":"Selinexor for the treatment of multiple myeloma","volume":"21","author":"Podar","year":"2020","journal-title":"Expert Opin Pharmacother"},{"issue":"22","key":"2023120815070749300_hem2023000444C20","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood.V128.22.491.491","article-title":"Selinexor and low dose dexamethasone (Sd) in patients with lenalidomide, pomalidomide, bortezomib, carfilzomib and anti-CD38 Ab refractory multiple myeloma (MM): STORM Study","volume":"128","author":"Vogl","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2023120815070749300_hem2023000444C21","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1016\/j.clml.2022.01.014","article-title":"Guidance for use and dosing of selinexor in multiple myeloma in 2021: consensus from international myeloma foundation expert roundtable","volume":"22","author":"Nooka","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 1","key":"2023120815070749300_hem2023000444C22","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood-2021-149423","article-title":"Carfilzomib, pomalidomide and dexamethasone (KPd) in patients with first progression of multiple myeloma refractory to bortezomib and lenalidomide. Final report of the EMN011\/HOVON114 trial [abstract]","volume":"138","author":"Sonneveld","year":"2021","journal-title":"Blood"},{"issue":"17","key":"2023120815070749300_hem2023000444C23","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"2023120815070749300_hem2023000444C24","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2023120815070749300_hem2023000444C25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-134538","article-title":"Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial","volume":"136","author":"Perrot","year":"2020","journal-title":"Blood"},{"issue":"2","key":"2023120815070749300_hem2023000444C26","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"issue":"15","key":"2023120815070749300_hem2023000444C27","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s40265-020-01404-x","article-title":"Belantamab mafodotin: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"issue":"suppl 1","key":"2023120815070749300_hem2023000444C28","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1182\/blood-2019-123705","article-title":"Synergistic activity of belantamab mafodotin (anti-BCMA immuno-conjugate) with PF-03084014 (gamma-secretase inhibitor) in Bcma-expressing cancer cell lines","volume":"134","author":"Eastman","year":"2019","journal-title":"Blood"},{"issue":"10","key":"2023120815070749300_hem2023000444C29","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1158\/1535-7163.MCT-21-0035","article-title":"Belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated antitumor responses in vivo","volume":"20","author":"Montes de Oca","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"22","key":"2023120815070749300_hem2023000444C30","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1002\/cncr.33809","article-title":"Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study","volume":"127","author":"Lonial","year":"2021","journal-title":"Cancer"},{"key":"2023120815070749300_hem2023000444C31","doi-asserted-by":"crossref","first-page":"678634","DOI":"10.3389\/fonc.2021.678634","article-title":"Ocular toxicity of belantamab mafodotin, an oncological perspective of management in relapsed and refractory multiple myeloma","volume":"11","author":"Wahab","year":"2021","journal-title":"Front Oncol"},{"key":"2023120815070749300_hem2023000444C32","author":"GSK provides update on DREAMM-3 phase III trial for Blenrep in relapsed\/refractory multiple myeloma","year":"2022"},{"key":"2023120815070749300_hem2023000444C33","author":"BLENREP (belantamab mafodotin): EU summary of product characteristics"},{"issue":"8","key":"2023120815070749300_hem2023000444C34","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"10297","key":"2023120815070749300_hem2023000444C35","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"16","key":"2023120815070749300_hem2023000444C36","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s40265-022-01793-1","article-title":"Teclistamab: first approval","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"issue":"4","key":"2023120815070749300_hem2023000444C37","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"2023120815070749300_hem2023000444C38","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"17","key":"2023120815070749300_hem2023000444C39","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174249","article-title":"T-cell-based cellular immunotherapy of multiple myeloma: current developments","volume":"14","author":"Simmons","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"suppl 1","key":"2023120815070749300_hem2023000444C40","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2021-146210","article-title":"Bortezomib, lenalidomide and dexamethasone (VRd) followed by ciltacabtagene autoleucel versus Vrd followed by lenalidomide and dexamethasone (Rd) maintenance in patients with newly diagnosed multiple myeloma not intended for transplant: a randomized, phase 3 study (CARTITUDE-5) [abstract]","volume":"138","author":"Dytfeld","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2023120815070749300_hem2023000444C41","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1182\/blood-2022-162469","article-title":"KarMMa-2 cohort 2a: efficacy and safety of idecabtagene vicleucel in clinical high-risk multiple myeloma patients with early relapse after frontline autologous stem cell transplantation [abstract]","volume":"140","author":"Usmani","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2023120815070749300_hem2023000444C42","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/blood-2020-139009","article-title":"KarMMa-4: idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, in high-risk newly diagnosed multiple myeloma [abstract]","volume":"136","author":"Usmani","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2023120815070749300_hem2023000444C43","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.1182\/blood-2021-147412","article-title":"KarMMa-7, a phase 1\/2, dose-finding and dose-expansion study of combination therapies with idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy for relapsed\/refractory multiple myeloma (RRMM) [abstract]","volume":"138","author":"Raje","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2023120815070749300_hem2023000444C44","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood-2021-150519","article-title":"Elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients with relapsed or refractory multiple myeloma: results from Magnetismm-1 [abstract]","volume":"138","author":"Sebag","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2023120815070749300_hem2023000444C45","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"suppl 1","key":"2023120815070749300_hem2023000444C46","doi-asserted-by":"crossref","first-page":"10172","DOI":"10.1182\/blood-2022-166854","article-title":"Magnetismm-4: an open label, phase 1B\/2 umbrella study of elranatamab in combination with other anti-cancer treatments for patients with multiple myeloma [abstract]","volume":"140","author":"Landgren","year":"2022","journal-title":"Blood"},{"issue":"16 suppl","key":"2023120815070749300_hem2023000444C47","doi-asserted-by":"crossref","first-page":"tps8074","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8074","article-title":"MagnetisMM-5: an open-label, multicenter, randomized phase 3 study of elranatamab as monotherapy and in combination with daratumumab in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"Grosicki","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16 suppl","key":"2023120815070749300_hem2023000444C48","doi-asserted-by":"crossref","first-page":"TPS8072","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8072","article-title":"MajesTEC-3: randomized, phase 3 study of teclistamab plus daratumumab versus investigator's choice of daratumumab, pomalidomide, and dexamethasone or daratumumab, bortezomib, and dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"Mateos","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16 suppl","key":"2023120815070749300_hem2023000444C49","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.1200\/JCO.2023.41.16_suppl.8003","article-title":"Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated TRIMM-2 results [abstract]","volume":"41","author":"Dholaria","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16 suppl","key":"2023120815070749300_hem2023000444C50","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2023.41.16_suppl.8002","article-title":"First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed\/refractory multiple myeloma (RRMM) [abstract]","volume":"41","author":"Cohen","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/443\/2175922\/443epperly.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/443\/2175922\/443epperly.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:11:54Z","timestamp":1702048314000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2023\/1\/443\/506433\/Considerations-for-next-therapy-after-anti-CD38"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12,8]]},"published-print":{"date-parts":[[2023,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2023000444","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12,8]]},"published":{"date-parts":[[2023,12,8]]}}}